ClinicalTrials.gg
CompletedNCT05079919Updated Feb 10, 2026

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

A Phase 3 interventional study of Olezarsen and Placebo in Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 209 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..

Enrollment
3rd of 12
617 · median 114
Started
2021
the only one that year
Phase 3
5 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 5 in phase 3, and was the 7th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled study in 617 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 78 weeks, which includes an up to 12-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment.

03

Conditions studied

  • Severe Hypertriglyceridemia

Browse trials for

Keywords

  • ISIS 678354
  • Fasting Triglycerides
  • Apolipoprotein C-III
  • Very Low-Density Lipoprotein Cholesterol
  • High-Density Lipoprotein-Cholesterol
  • Non-High-Density Lipoprotein-Cholesterol
  • Olezarsen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
  • Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study.

Key Exclusion Criteria:

  • (HbA1c) ≥ 9.5% at Screening
  • or aspartate aminotransferase > 3.0 ×
  • Total > upper limit of normal unless due to Gilbert's syndrome
  • Estimated \< 30 mL/min/1.73 m\^2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Olezarsen

    Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.

    Drug: Olezarsen

  • Placebo comparator
    Placebo

    Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.

    Drug: Placebo

Interventions

  • Olezarsen will be administered by SC injection.

    Also known as: AKCEA-APOCIII-LRx, ISIS 678354

  • DrugPlacebo

    Olezarsen-matching placebo will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Fasting TG Compared to Placebo

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Percent Change from Baseline in Fasting TG Compared to Placebo

    Time frame: Baseline and Month 12

  2. Percent Change from Baseline in Fasting Apolipoprotein C-III (ApoC-III), Remnant Cholesterol and Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) Compared to Placebo

    Time frame: Baseline, Month 6 and 12

  3. Proportion of Patients Who Achieve Fasting TG <500 mg/dL (5.65 mmol/L) Compared to Placebo

    Time frame: Month 12

  4. Proportion of Participants Who Achieve Fasting TG < 880 mg/dL (10 mmol/L) Compared to Placebo in the Subgroup of Participants with Baseline TG ≥ 880 mg/dL

    Time frame: Month 12

  5. Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo

    Time frame: Week 1 through Week 53

  6. Absolute Change in Hepatic Fat Fraction (HFF) Between Olezarsen Treatment Group and Pooled Placebo

    Time frame: Baseline through Month 12

07

Study locations

209 sites
  • Accel Research Sites Network
    Birmingham, Alabama 35216, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Velocity Clinical Research
    Chula Vista, California 91911, United States
  • Diabetes/Lipid Management & Research Center
    Huntington Beach, California 92648, United States
  • University of California, San Diego (UCSD)
    La Jolla, California 92037, United States
  • LA Universal Research Center, Inc.
    Los Angeles, California 90057, United States
  • America Clinical Trials
    Tarzana, California 91356, United States
  • Excel Medical Clinical Trials, LLC
    Boca Raton, Florida 33434, United States
  • Southeast Clinical Research LLC
    Chiefland, Florida 32626, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Finlay Medical Research
    Miami, Florida 33126, United States
  • Innovia Research Center, INC
    Miramar, Florida 33027, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34471, United States
  • IMA Clinical Research
    St. Petersburg, Florida 33709, United States
  • VICIS Clinical Research
    Tampa, Florida 33614, United States
  • Bayside Clinical Research
    Trinity, Florida 34655, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • IMA Clinical Research Chicago
    Chicago, Illinois 60602, United States
  • Affinity Health
    Oak Brook, Illinois 60523, United States
  • West Broadway Clinic
    Council Bluffs, Iowa 51501, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Clinical Trials of America, LLC
    Monroe, Louisiana 71201, United States
  • Continental Clinical Solutions
    Towson, Maryland 21204, United States
  • University of Michigan Hospital and Health Systems/ Dept. of Pharmacy-Research Pharmacy
    Ann Arbor, Michigan 48109, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • IMA Clinical Research
    St Louis, Missouri 63117, United States
  • Bryan Medical Center Clinical Research
    Lincoln, Nebraska 68506, United States
  • Palm Research Center, INC.
    Las Vegas, Nevada 89148, United States
  • Hudson County Clinical Trials Research Center
    Union City, New Jersey 07087, United States
  • Modern Medicine
    Brooklyn, New York 11235, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • Circuit Clinical (Crystal Run Healthcare)
    Middletown, New York 10941, United States
  • NYU Langone
    New York, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • Circuit Clinical
    Niagara Falls, New York 14304, United States
  • Modern Medical
    Syosset, New York 11791, United States
  • Novant Health Cancer Institute Elizabeth Investigational Drug Services
    Charlotte, North Carolina 28204, United States
  • Cone Medical Center
    Greensboro, North Carolina 27401, United States
  • Clinical Trials of America, LLC
    Mount Airy, North Carolina 27030, United States
  • Wake Forest University Health Sciences
    Salem, North Carolina 27157, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • Summit Research Group, LLC
    Munroe Falls, Ohio 44262, United States
  • Hightower Clinical Trial Services
    Oklahoma City, Oklahoma 73102, United States
  • Velocity Clinical Research
    Medford, Oregon 97504, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Chattanooga Research & Medicine, PLLC
    Chattanooga, Tennessee 37404, United States
  • Velocity Clinical Research
    Cedar Park, Texas 78613, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Medicus Alliance Clinical Research
    Sugar Land, Texas 77478, United States
  • Velocity Clinical
    West Jordan, Utah 84088, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • York Clinical Research LLC
    Norfolk, Virginia 23510, United States
  • West Virginia University Heart and Vascular Institute
    Morgantown, West Virginia 26506, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Royal North Shoe Hospital
    Saint Leonards, New South Wales 2065, Australia
  • Dr. Heart Pty Ltd at Cholesterol Care Australia
    Woolloongabba, Queensland 4102, Australia
  • Monash Medical Centre
    Clayton S., Victoria 3168, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
  • MHAT Blagoevgrad AD
    Blagoevgrad, 2700, Bulgaria
  • Medical Center Doctor Staykov EOOD
    Burgas, 8008, Bulgaria
  • Medical Center Diamedical 2013 OOD
    Dimitrovgrad, 6400, Bulgaria
  • MHAT "Dr. Tota Venkova" AD
    Gabrovo, 5300, Bulgaria
  • Medical Center "Hera" EOOD
    Montana, 3400, Bulgaria
  • SHAT "Special Medic" Ltd
    Plovdiv, 4000, Bulgaria
  • Medical Center Rusemed EOOD
    Rousse, 7000, Bulgaria
  • DCC 1 Sliven
    Sliven, 8800, Bulgaria
  • Gabriela Zhelyazkova
    Sliven, 8800, Bulgaria
  • Medical Center Smolyan Clinical Research OOD
    Smolyan, 4700, Bulgaria
  • Medical Center Endomedical EOOD
    Sofia, 1606, Bulgaria
  • Medical Centar "KALIMAT"
    Sofia, 1680, Bulgaria
  • MC Doctor Kalchev OOD
    Sofia, 1700, Bulgaria
  • UMHAT Sofiamed OOD
    Sofia, 1797, Bulgaria
  • New Rehabilitation Center
    Stara Zagora, 6000, Bulgaria
  • UMHAT Prof. Dr. Stoyan Kirkovich AD, Clinic of Cardiology
    Stara Zagora, 6000, Bulgaria
  • Medical Centre Nevromedics EOOD
    Veliko Tarnovo, 5006, Bulgaria
  • Arc Biosystems
    Vancouver, British Columbia V6Z 2C7, Canada
  • Canadian Phase Onward Inc
    Toronto, Ontario M3J 0K2, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Institut de recherches cliniques de Montréal (IRCM)
    Montreal, Quebec H2W 1R7, Canada
  • Clinique des Maladies Lipidiques de Quebec Inc.
    Québec, Quebec G1V 4W2, Canada
  • MEDICUS SERVICES s.r.o.
    Brandýs nad Labem, 250 01, Czechia
  • EDUMED s.r.o.
    Hradec Králové, 500 02, Czechia
  • Fakultní nemocnice Hradec Králové
    Hradec Králové, 500-05, Czechia
  • EDUMED s.r.o.
    Náchod, 547 01, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, 70852, Czechia
  • Vseobecna fakultni nemocnice
    Prague, 128 08, Czechia
  • Lekarna Poliklinika Hurka
    Prague, 15800, Czechia
  • Interni Ambulance
    Uherské Hradiště, 686 01, Czechia
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Aarhus University Hospital
    Aarhus, 8200, Denmark
  • Esbjerg Hospital
    Esbjerg, 6700, Denmark
  • Bispebjerg Hospital
    Frederiksberg, 2000, Denmark
  • Herlev Hospital
    Herlev, 2730, Denmark
  • Godstrup Regional Hospital
    Herning, 7400, Denmark
  • Regionshospitalet Viborg
    Viborg, 8800, Denmark
  • Turku University Hospital
    Turku, 20520, Finland

Showing the first 100 of 209 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, Zimerman A, Waldman E, Weinland J, Murphy SA, Goodrich EL, Zhang S, Xia S, Li D, Goldberg AC, Goudev A, Badimon L, Kiss RG, Vrablik M, Gaudet D, Moulin P, Stroes ESG, Banach M, Cohen H, Blom D, Charng MJ, Nordestgaard BG, Nicholls SJ, Tsimikas S, Giugliano RP, Sabatine MS; CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026 Jan 29;394(5):429-441. doi: 10.1056/NEJMoa2512761. Epub 2025 Nov 8. PubMed 41211918 ↗
  • Marston NA, Bergmark BA, Alexander VJ, Karwatowska-Prokopczuk E, Kang YM, Moura FA, Prohaska TA, Zimerman A, Zhang S, Murphy SA, Tsimikas S, Giugliano RP, Sabatine MS. Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. Am Heart J. 2025 Aug;286:125-135. doi: 10.1016/j.ahj.2025.03.003. Epub 2025 Mar 9. PubMed 40064331 ↗

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2024, 35 months.

Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's 35 months is above that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Oct 15, 2021
StartActual
Oct 25, 2021
Primary completionActual
Oct 22, 2024
CompletionActual
Jul 8, 2025
Results delay requested
Oct 17, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05079919
Responsible party
Sponsor
First posted
Oct 15, 2021
Start date
Oct 25, 2021
Primary completion
Oct 22, 2024
Completion
Jul 8, 2025
Last update
Feb 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olezarsen

Start the discussion